ALPRESS - ALPRESS - CT 12020 & 12437 - English version

pages

English

Documents

2012

Écrit par
Has

Publié par
haute-autorite-sante-maladies-vasculaires

Lire un extrait

Obtenez un accès à la bibliothèque pour le consulter en ligne En savoir plus

Découvre YouScribe et accède à tout notre catalogue !

Je m'inscris

Découvre YouScribe et accède à tout notre catalogue !

Je m'inscris

pages

English

Documents

2012

Lire un extrait

Obtenez un accès à la bibliothèque pour le consulter en ligne En savoir plus

Publié par

haute-autorite-sante-maladies-vasculaires

Publié le

18 juillet 2012

Nombre de lectures

Licence :

En savoir +

Langue

English

Introduction ALPRESS LP 2.5 mg, prolonged release osmotic tablet B/30 tablets (CIP code: 331 177-5) B/90 tablets (CIP code: 372 965-8) ALPRESS LP 5 mg, prolonged release osmotic tablet B/30 tablets (CIP code: 331 172-3) B/90 tablets (CIP code: 372 966-4) Posted on Mar 19 2013 Active substance (DCI) prazosin base ATC Code C02CA01 Laboratory / Manufacturer PFIZER ALPRESS LP 2.5 mg, prolonged release osmotic tablet B/30 tablets (CIP code: 331 177-5) B/90 tablets (CIP code: 372 965-8) ALPRESS LP 5 mg, prolonged release osmotic tablet B/30 tablets (CIP code: 331 172-3) B/90 tablets (CIP code: 372 966-4) Posted on Mar 19 2013

Voir

Publié par

haute-autorite-sante-maladies-vasculaires

Publié le

18 juillet 2012

Licence :

En savoir +

Langue

English

Hypertension artérielle Médecine

The legally binding text is the original French version TRANSPARENCY COMMITTEE

OPINION 18 July 2012 Examination of the file for proprietary medicinal products registered for a period of 5 years with effect from 26 March 2007 (Official Gazette of 22 April 2008) ALPRESS LP 2.5 mg, prolonged release osmotic tablet B/30 tablets (CIP code: 331 177-5) B/90 tablets (CIP code: 372 965-8) ALPRESS LP 5 mg, prolonged release osmotic tablet B/30 tablets (CIP code: 331 172-3) B/90 tablets (CIP code: 372 966-4) Applicant: PFIZER prazosin base ATC code:C02CA01 (peripherally acting adrenolytic antihypertensive/alpha blockers) List I B/30: Hospitals, National Health Insurance (65%) B/90: National Health Insurance (65%) Date of Marketing Authorisation (national): 22 June 1988 Amendments of 13 July 2010, 11 July 2011 and 26 August 2011, detailed in the appendix. Reasons for request: - Re-assessment of the Actual Benefit following the instruction of 7 May 2011 from the Directorate of Social Security and Directorate-General for Health. - Renewal of inclusion on the list of medicines refundable by National Health Insurance. Medical, Economic and Public Health Assessment Division

1/12

Voir